By Nigam Arora NVO, the maker of weight loss drug Wegovy, is buying AKRO. The deal is for $60 per share. The deal consists of $54 per share in cash to be paid on closing and $6 per share in cash upon U.S. regulatory approval of efruxifermin drug cirrhosis. What To
By Nigam Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning
By Nigam Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning
By Nigam Arora To gain an edge, this is what you need to know today. Deploy Cash And Reduce Hedges Please see the Protection Band And What To Do Now section below. The change is triggered by the prospect of China tariffs being reduced to 10%. Great Deal For China Please
By Nigam Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning
By Nigam Arora & Dr. Natasha Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules
By Nigam Arora & Dr. Natasha Arora To gain an edge, this is what you need to know today. Avoid The Common Investment Mistake Please click here for a chart of 20+ year Treasury bond ETF (TLT). Note the following: Countless investors and investment advisors are losing significant money because they are
By Nigam Arora & Dr. Natasha Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules
By Nigam Arora & Dr. Natasha Arora To gain an edge, this is what you need to know today. Hopium Meeting Reality Please click here for a chart of Hims & Hers Health stock (HIMS). Note the following: In many areas, hopium from President Trump is justified. However, the momo crowd has
By Nigam Arora & Dr. Natasha Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules